YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Guardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes in major global geographies This latest approval marks Guardant's 31st CDx approval PALO ALTO, Calif., October 08, 2026--(BUSINESS WIRE)--Gu…
Q2 Testing & Diagnostics Services Earnings: RadNet (NASDAQ:RDNT) Earns Top Marks The end of the earnings season is always a good time to take a step back and see who shined (and who didn't). Let's take a look at how testing & diagnostics s…
Company Logo Newly released 9th edition sizes the market at US$8.14 billion in 2025, with ctDNA leading and analysis of AI's impact. Profiles 117 companies including Guardant Health, Natera and Exact Sciences. Dublin, Oct. 08, 2026 (GLOBE…
The S&P 500 hit a high as the stock market extended a win streak. Astera Labs, GE Vernova and Arista Networks led AI stock buys. Continue Reading
The S&P 500 hit a high as the stock market extended a win streak. Astera Labs, GE Vernova and Arista Networks led AI stock buys. Continue Reading
The S&P 500 hit a high as the stock market extended a win streak. Astera Labs, GE Vernova and Arista Networks led AI stock buys. Continue Reading
First published prospective, multicenter study of Guardant Reveal in resected melanoma demonstrates 81% sensitivity for distant recurrence and 100% post-treatment specificity Molecular residual disease detection approximately four weeks af…
3 Cash-Burning Stocks with Questionable Fundamentals Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt…
A few IBD 50 stocks are showing unusually narrow trading. Continue Reading
1 Mid-Cap Stock for Long-Term Investors and 2 We Ignore Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense com…
Coverbase Brian Shaw and Constantine Malaxos join as enterprise customers expand across financial services, healthcare, and technology SAN FRANCISCO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Coverbase, AI engineered for third-party risk manageme…
Grail stock rose 35% this week as the Food and Drug Administration considers the company’s cancer blood test. Continue Reading
The Nasdaq hit a new high with memory giants Sandisk and Micron flashing buy signals. But financials are struggling. Continue Reading
The Nasdaq hit a new high with memory giants Sandisk and Micron flashing buy signals. But financials are struggling. Continue Reading
This article first appeared on GuruFocus. Cathie Wood's Ark Invest made a notable shift inside its technology portfolio last week, adding heavily to CoreWeave while cutting several other AI and technology positions. Ark bought about 239,00…
Guardant Health has also earned a spot on the Investor's Business Daily Leaderboard. Earlier this month, the FDA approved Guardant360 CDx as a companion diagnostic for Etcamah from AstraZeneca in advanced or metastatic breast cancer. Guard…
1 Unpopular Stock That Should Get More Attention and 2 We Question When Wall Street turns bearish on a stock, it's worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms w…
Guardant Health (NasdaqGS:GH) received FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic in advanced HR-positive, HER2-negative breast cancer. The decision makes Guardant360 CDx the first FDA approved liquid biop…
Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH) Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let's have a look at Guardant Health (NAS…
Guardant Health provides services across the cancer continuum. Shares are near a buy point of 176.58 after a breakout. Continue Reading
The S&P 500 and Nasdaq undercut key support as oil prices and Treasury yields jumped. How will bonds react to the Federal Reserve decision? Continue Reading
The S&P 500 and Nasdaq undercut key support as oil prices and Treasury yields jumped. How will bonds react to the Federal Reserve decision? Continue Reading
The S&P 500 and Nasdaq undercut key support as oil prices and Treasury yields jumped. How will bonds react to the Federal Reserve decision. Continue Reading
The S&P 500 and Nasdaq undercut key support as oil prices and Treasury yields jumped. How will bonds react to the Federal Reserve decision. Continue Reading
Guardant Health (GH) stands to benefit from AstraZeneca's (AZN) failed Serena-4 trial because the re PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Second largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholders Milestone marks rapid adoption by insurers for the most clinica…
Research highlights the significance of genomic and epigenomic profiling approaches to characterize lung tumors, identify biomarkers, and support risk stratification Real-world studies examine the complementary roles of plasma- and tissue-…
Earning the highest five-star recognition alongside only 12 other companies in the biotechnology category Recognition underscores Guardant's leadership in precision oncology including patient growth and years of sustained R&D investment PA…
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fu…
1 Growth Stock to Add to Your Roster and 2 We Turn Down Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVI…
Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the "Artisan Mid Cap Fund". The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March low…
[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello/Getty Images News Cathie Wood’s Ark Invest leaned further into high-growth themes, including space, fintech, crypto, and biotechnology…
Guardant Health, Inc. (NASDAQ:GH) faces a costly legal setback after a US court ordered the cancer-testing company to pay more than $245.2 million in a DNA-sequencing patent dispute. The final judgment upheld a 2023 jury verdict finding th…
Approval recommends repeat Guardant360 CDx testing every three months during therapy to detect emerging ESR1 mutations before clinical or radiographic disease progression In the Phase III SERENA-6 trial, ctDNA-guided treatment using Guarda…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images With the second-quarter earnings season now largely behind us, investors are turning their attention to how healthcar…
Largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholders Increasing total covered Shield lives ages 45 and older to approximate…